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Alba Ramirez-Sarmiento,1 Mauricio Orozco-Levi,1 Eric C. Walter,2 Margaret A. Au,3
Jason W. Chien2,4We conducted a 15-year retrospective cohort study to determine the prevalence of restrictive lung disease
before allogeneic hematopoietic cell transplantation (HCT), and to assess whether this was a risk factor for
poor outcomes. A total of 2545 patients were eligible for the analysis. Restrictive lung disease was defined as
a total lung capacity (TLC)\ 80% of predicted normal. Chest x-rays and /or computed tomography (CT)
scans were reviewed for all restricted patients to determine whether lung parenchymal abnormalities
were unlikely or highly likely to cause restriction. Multivariate Cox proportional hazard and sensitivity anal-
yses were performed to assess the relationship between restriction and early respiratory failure and nonre-
lapse mortality. Restrictive lung disease was present in 194 subjects (7.6%) before HCT. Among these cases,
radiographically apparent abnormalities were unlikely to be the cause of the restriction in 149 subjects (77%).
In unadjusted and adjusted analyses, the presence of pulmonary restriction was significantly associated with
a 2-fold increase in risk for early respiratory failure and nonrelapse mortality, suggesting that these outcomes
occurring in the absence of radiographically apparent abnormalities may be related to respiratory muscle
weakness. These findings suggest that pulmonary restriction should be considered a risk factor for poor out-
comes after transplantation.
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Pulmonary function tests (PFTs) are routinely
performed before allogeneic hematopoietic cell trans-
plantation (HCT) to screen for underlying respiratory
abnormalities and to provide baseline lung functionGroup of Research in Injury and ImmuneResponse (LIF),
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6/j.bbmt.2009.09.016measurements for comparison when transplantation-
related pulmonary complications are suspected [1].
Several studies examining the predictive value of pre-
transplantation PFTs for posttransplantation compli-
cations have demonstrated that impaired lung
function before transplantation increases the risk for
posttransplantation pulmonary complications and
mortality [2-14]. However, the majority of these previ-
ous studies focused primarily on the 1-second forced
expiratory volume (FEV1) [2,12,14] and the carbon
monoxide diffusion capacity (DLCO) [10-12,14] as
a surrogate measure of pulmonary gas exchange, or
on the effect of specific physiological patterns, such
as the effect of pretransplantation airflow obstruction,
on posttransplantation outcome [3,4,9,12]. Although
a few studies have evaluated the relationship between
pretransplantation pulmonary restriction and post-
transplantation outcomes [2,12,15], the prevalence of
restrictive lung disease before allogeneic HCT and
its influence on transplantation outcome have not
been well described.
Multiple factors can result in a restrictive pattern
on pulmonary function testing before HCT, including
advanced intrathoracic malignant lesions, spinal cord
compression, prior treatments (eg, chemotherapy,199
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spiratory disease or infection, and/or myopathies/de-
conditioning resulting in respiratory muscle
weakness [1]. In a recent study, we found evidence
that a reduced total lung capacity (TLC), which de-
fines pulmonary restriction, before allogeneic HCT
may influence posttransplantation outcome [8]. These
preliminary data and the current gap in knowledge
regarding restrictive pulmonary processes and alloge-
neic HCT outcomes prompted us to conduct a 15-
year retrospective cohort study to determine the
prevalence of restrictive lung disease before allogeneic
HCT, and to assess whether this is a pretransplantation
risk factor for 2 major transplantation outcomes: early
respiratory failure and nonrelapse mortality (NRM).METHODS
Patient Selection
All patients who underwent a first allogeneic HCT
at Fred Hutchinson Cancer Research Center/Seattle
Cancer Care Alliance (the ‘‘Center’’) between July 6,
1992, and July 6, 2005, were eligible for this analysis
(n 5 2847). Patients under age 15 years (n 5 170),
and those without a pretransplantation assessment of
pulmonary static lung volume (n 5 132), were ex-
cluded. A total of 2545 patients were included in the
final analyses.
Clinical Data
All clinical data were prospectively collected and
retrospectively reviewed. The patient’s underlying dis-
ease state was categorized as low risk, intermediate
risk, or high risk, as described previously [8,16]. Donor
match status was determined according to donor–
recipient ABO compatibility and HLA-A, -B, and
-DR status. Stem cell sources were classified as bone
marrow (BM), peripheral blood stem cell (PBSC),
other (including cord blood [CB]), or a combination
of BM and PBSC. Conditioning regimens were classi-
fied as reduced intensity (RIC) or myeloablative (MA).
Patients in the MA conditioning group included pa-
tients that received either a total body irradiation
(TBI)- or non–TBI-based regimen. Patients in the
RIC group received 2 Gy of TBI. Body mass index
(BMI) was calculated using weight and height and cat-
egorized as underweight (BMI\18.5), normal weight
(BMI 18.5-24.9), overweight (BMI 25.0-29.9), or
obese (BMI . 30.0) [17].
Pulmonary Function Testing
According to standard transplantation protocol
at our Center, all patients underwent pulmonary func-
tion testing before transplantation when possible. The
PFT values obtained before and closest to the time oftransplantation were used in the analysis. In those pa-
tients who received a bronchodilator challenge, the
prebronchodilator values were used. All PFTs were
performed at our Center according to the American
Thoracic Society (ATS) guidelines [18] using a Sensor-
medics 2100 (Sensormedics, Yorba Linda, CA) between
July 1991, and August 1999, and a Sensormedics V-Max
22 with Autobox 6200 between September 1999, and
July 2005. Published equations for adults were used to
determine predicted values of FEV1, forced vital capac-
ity (FVC), TLC, residual volume (RV), and DLCO
[18-20]. All DLCO measurements were corrected for
the hemoglobin measurement obtained closest to the
time of measurement of diffusion capacity, but not
alveolar volume [21].
Chest Imaging
Chest imaging data were reviewed for all patients
determined to have pretransplantation restrictive
lung disease by PFT results. Data were obtained by re-
viewing chest x-ray and computed tomography (CT)
reports when available, and by reviewing clinical notes
when imaging reports were not available. Imaging was
performed within 30 days before or after HCT in the
majority of the subjects (96%). When both chest
x-ray and chest CT results were available within the
same time window, CT results were used preferen-
tially. All reports were independently and collectively
reviewed by 3 pulmonologists and classified as having
either a high probability or a low probability that pa-
renchymal lung disease or chest wall deformities
were contributing significantly to the restrictive lung
disease. Nodules, lobar infiltrates, cavities\ 4 cm in
size, and small effusions were classified as low proba-
bility. Evidence of thoracic surgery, elevated dia-
phragm, diffuse interstitial lung disease, pulmonary
fibrosis, central masses, and moderate to severe pleural
effusions were classified as high probability.
Restrictive Pulmonary Disease Definitions
Restrictive lung disease was defined according to
ATS/European Respiratory Society (ERS) criteria as
a TLC\ 80% (definition 1) [20,22]. To examine the
possible association between respiratory muscle weak-
ness and outcome, we performed a sensitivity analysis
using 2 additional definitions of restrictive lung dis-
ease. The first definition required both a TLC\80%
and a FEV1/FVC ratio . 0.7 (definition 2). The sec-
ond alternative definition required the same, as well
as a low-probability chest image that provided no evi-
dence of a parenchymal explanation for the restrictive
pattern (definition 3).
Outcome Definitions
Patients were considered to have developed early
respiratory failure if they required . 24 hours of
Table 1. Patient Pretransplantation Characteristics
Characteristic n (%) or Mean ± SD
Total number of patients 2545 (100)
Age at transplantation, years 42 ± 12.3
White race 2141 (84.1)
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the first 120 days after HCT. NRM was defined as
mortality in patients who did not experience relapse
of their underlying malignancy during the follow-up
period.Male sex 1487 (58.4)
Donor type
HLA-matched related 1690 (66.4)
HLA-mismatched related 565 (22.2)
Unrelated 237 (9.3)
Conditioning regimen
Myeloablative 2338 (92)
Nonmyeloablative 207 (8)Statistical Methods
All statistical analyses were performed using SPSS
15.0 for Windows (SPSS, Chicago, IL) and Stata/IC
10.0 for Windows (StataCorp, College Station, TX).
Two-sided P values# .05 were considered statistically
significant. Diagnosis, disease status, and disease risk
were evaluated as categorical variables. PFT parame-
ters and BMI were evaluated as both continuous and
categorical variables. Pearson’s c2 test and one-way
analysis of variance were used to compare categorical
and continuous variables, respectively. To evaluate
a possible association between respiratory muscle
weakness and worse outcome, we performed a sensitiv-
ity analysis using 3 successively more stringent defini-
tions for a restrictive pattern likely caused by
respiratory muscle weakness. Cox proportional haz-
ards models were used to assess the relationship
between pulmonary restriction and the outcomes of
interest. Patients who experienced disease relapse
were censored at the time of relapse for theNRM anal-
ysis. To account for potential changes in clinical prac-
tice over time, the year of transplantation was
considered a categorical variable in the analysis. The
incidence of developing early respiratory failure and
NRM according to lung function parameters were
plotted using cumulative incidence curves, with dis-
ease relapse treated as a competing event for NRM
and all-cause mortality treated as a competing event
for respiratory failure. Cumulative incidence curves
were compared using the method of Gray [25].RESULTS
Clinical Characteristics and Baseline Lung
Function
Table 1 summarizes pretransplantation clinical
characteristics of all patients. The mean (6 standard
deviation) number of days between pulmonary func-
tion testing and transplantation was 24 6 9 days.
Restrictive lung disease, defined as a TLC \ 80%,
was present in 194 patients (7.6%) (Table 2). The
prevalence of restrictive lung disease increased with
increasing disease risk (P\ .001; Table 3), from 4%
in low-risk patients to 7% in intermediate-risk patients
and 12% in high-risk patients. A total of 107 chest
x-rays and 81 chest CT scans were reviewed for the
194 patients with a restrictive pattern. Six patients
did not have any radiographic images available for
review. The majority of patients with a TLC\ 80%had normal or near-normal chest radiographic
findings (n 5 149; 77%) and were categorized as
having a low likelihood of parenchymal lung disease
or a chest wall deformity being a cause of pulmonary
restriction. The remainder of the patients with
a TLC\ 80% (n 5 39; 20%) had prior thoracic sur-
gery or radiographic evidence of a mediastinal, lung,
or pleural abnormality and were classified as having
a high likelihood of parenchymal lung disease or a chest
wall deformity being a significant cause of pulmonary
restriction. Patients with the most severely diminished
TLCwere more likely to have abnormal chest imaging
results (31% vs 5%; P\ .001).
Among pretransplantation characteristics, only
disease diagnosis and stage were significantly associ-
ated with a TLC \ 80% (Table 3). Although the
majority of the patients were in the highest TLC cate-
gory, a larger percentage of those with Hodgkin dis-
ease (HD) had a pretransplantation TLC in the
lowest category (P\ .001). Similarly, there also was
a significant association between baseline TLC and
disease status at transplantation (P\ .001). To facili-
tate further analysis, we integrated the pretransplanta-
tion diagnosis and disease status into a composite
variable—disease risk—and confirmed the association
with pretransplantation TLC (Table 3). Because phys-
iological deconditioning or pulmonary injury from
significant pretreatment can result in a restrictive pat-
tern and influence the risk of developing the outcome,
disease risk represents a potential confounding vari-
able. Because of the low number of patients in each
TLC category below 80%, we also dichotomized the
TLC categories into $ 80% versus\80% for the re-
maining analyses.
Pretransplantation Restrictive LungDisease and
Early Respiratory Failure
Pretransplantation restrictive lung disease was sig-
nificantly associated with a higher risk of early respira-
tory failure (hazard ratio [HR]5 2.22; 95% confidence
interval [CI] 5 1.60-3.07; P\ .001) (Table 4). The
cumulative incidence of early respiratory failure
was significantly different between patients with
a pretransplantation TLC \ 80% and those with
Table 2. Distribution of PFT Parameters and Chest Imaging Findings According to Pretransplantation TLC Category
Pretransplantation TLC Category
$ 80% 70%-79% 60%-69% < 60% P Value*
Number of patients (%) 2351 (92.4) 134 (5.3) 39 (1.5) 21 (0.8)
Mean BMI (± SD) 27 ± 5 28 ± 6 26 ± 5 23 ± 4 .010
Mean percent of predicted (± SD)
FEV1 94 ±13 74 ± 9 61 ± 11 53 ± 20 <.0001
FVC 100 ±13 75 ± 9 63 ± 12 55 ± 21 <.0001
FEV1/FVC ratio 0.77 ± 0.07 0.80 ± 0.05 0.80 ± 0.06 0.82 ± 0.07 <.0001
RV 100 ± 26 76 ± 17 76 ± 19 76 ± 28 <.0001
DLCO 90 ±17 74 ±20 62 ±13 54 ± 16 <.0001
Chest radiographic findings†
Low probability NA 113 (76) 29 (19) 7 (5) <.0001
High probability NA 18 (46) 9 (23) 12 (31) <.0001
NA indicates not available; PFT, pulmonary function test; TLC, total lung capacity; DLCO, carbon monoxide diffusion capacity; FEV1, 1-second forced
expiratory volume; FVC, forced vital capacity; RV, residual volume.
*The Pearson c2 test and one-way analysis of variance were used to compare categorical and continuous variables, respectively.
†Six patients did not have radiologic data available for review.
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ure 1A). In an attempt to isolate the effect of respira-
tory muscle weakness, we repeated this analysis using
progressively stringent criteria for restrictive lung dis-
ease.When restrictive lung disease was defined as both
a TLC \ 80% and an FEV1/FVC ratio . 0.7, it
remained significantly associated with a 2-fold increase
in risk for early respiratory failure (HR 5 2.19; 95%
CI5 1.57-3.06; P\ .001). Using these criteria for pul-
monary restriction, the cumulative incidence of early
respiratory failure remained significantly different be-
tween patients with and without pretransplantation
pulmonary restriction (P\ .0001) (Figure 1B). The
third analysis required a TLC \ 80%, an FEV1/
FVC ratio . 0.7, and a low-probability chestTable 3. Distribution of Diagnosis, Disease Status, and Disease Ris
Total $80%, n (%) 70%
Diagnosis
Chronic myelogenous leukemia 810 770 (95)
Acute myelogenous leukemia 747 695 (93)
Myelodysplastic syndrome 446 410 (92)
Acute lymphocytic leukemia 261 230 (88)
Non-Hodgkin lymphoma 147 129 (88)
Multiple myeloma 64 55 (86)
Chronic lymphocytic leukemia 50 46 (92)
Hodgkin disease 25 15 (60)
Disease status
Accelerated phase 139 132 (95)
Blast crisis 92 80 (87)
Chronic phase 581 560 (96)
De novo 34 30 (88)
Relapse 607 534 (88)
Remission 591 555 (94)
Unknown 43 39 (91)
Other 459 420 (92)
Disease risk
Low 724 693 (96)
Intermediate 995 926 (93)
High 808 715 (88)
TLC indicates total lung capacity.
*Pearson’s c2 test was used to compare categorical variables.radiograph. Although attenuated slightly, a restrictive
pattern remained significantly associated with an in-
creased risk of early respiratory failure (HR 5 1.84;
95% CI 5 1.25-2.71; P\ .002). Even under this defi-
nition of pulmonary restriction, patients with and
without pretransplantation pulmonary restriction still
had a significantly different cumulative incidence of
early respiratory failure (P 5 .012) (Figure 1C).
Given the potentially confounding effects of dis-
ease risk, we repeated these analyses after adjusting
for disease risk in the models. We also adjusted for
year of transplantation to account for any changes in
clinical practice over the duration of the study. These
adjustments reduced the point estimates; however, the
associations between pulmonary restriction and earlyk According to Pretransplantation TLC Category
Pretransplantation TLC Category
-80%, n (%) 60%-70%, n (%) <60%, n (%) P Value*
<.001
30 (4) 8 (1) 2 (<1)
39 (5) 10 (1) 3 (<1)
24 (5) 9 (2) 3 (<1)
21 (8) 7 (3) 3 (1)
7 (5) 2 (1) 4 (3)
5 (8) 2 (8) 2 (3)
3 (6) 0 (0) 1 (2)
6 (24) 1 (4) 3 (12)
<.001
5 (4) 1 (<1) 1 (<1)
8 (9) 3 (3) 1 (<1)
17 (3) 4 (<1) 0 (0)
1 (2) 3 (10) 0 (0)
47 (8) 11 (2) 15 (2)
27 (5) 8 (1) 1 (<1)
4 (9) 0 (0) 0 (0)
27 (6) 9 (2) 3 (<1)
<.001
23 (3) 8 (1) 0 (0)
50 (5) 15 (1) 4 (<1)
61 (8) 15 (2) 17 (2)
Table 4. Sensitivity Analysis of the Association between Pretransplantation Restriction and Early Respiratory Failure
Unadjusted Adjusted*
n (%) Events HR (95% CI) P Value HR (95% CI) P Value
TLC < 80%
No 2351 (92) 261 — —
Yes 194 (8) 43 2.22 (1.60-3.07) < .001 1.90 (1.36-2.65) < .001
TLC < 80% + FEV1/FVC > 0.7
No 2358 (93) 263 — —
Yes 185 (7) 41 2.19 (1.57-3.06) < .001 1.90 (1.35-2.66) < .001
TLC < 80% + FEV1/FVC > 0.7 + low-probability chest imaging
No 2396 (93) 275 — —
Yes 143 (6) 28 1.84 (1.25-2.71) .002 1.59 (1.07-2.37) .022
TLC indicates total lung capacity; FEV1, 1-second forced expiratory volume; FVC, forced vital capacity.
*Adjusted for disease risk and year.
Biol Blood Marrow Transplant 16:199-206, 2010 203Pulmonary Restriction and Mortality after HCTrespiratory failure remained statistically significant for
the first 2 definitions, and a trend toward significance
with a smaller effect size remained for the third defini-
tion (Table 4).
Because of fundamental differences in characteris-
tics among patients receiving anMA conditioning reg-
imen and those receiving a nonmyeloablative (NMA)
conditioning regimen, we also stratified the adjusted
analysis based on this criterion. Among patients who
received a MA conditioning regimen (n 5 2338), the
presence of pretransplantation pulmonary restriction
remained significantly associated with increased risk
for early respiratory failure in the adjusted analysis0
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Figure 1. Cumulative incidence curves for early respiratory failure (A, B, and
transplantation pulmonary restriction; the solid lines, patients without pretrans
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cumulative incidence of early respiratory failure (A, P\ .000; B, P\ .0001;
.0001; F, P\.0001).(definition 1: HR 5 1.67, 95% CI 5 1.43-1.95, P\
.001; definition 2: HR 5 1.68, 95% CI 5 1.43-1.96,
P\ .001; definition 3: HR 5 1.46, 95% CI 5 1.44-
1.98, P \ .001). Among patients who received an
RIC regimen (n 5 207), the presence of pretransplan-
tation pulmonary restriction according to definitions 1
and 2 was associated with an increased risk of early re-
spiratory failure. This difference was no longer statis-
tically significant in adjusted analyses (definition 1:HR
5 2.81, 95% CI 5 0.73-10.82, P 5 .134; definition 2:
HR5 1.80, 95%CI5 0.38-8.46, P5 .455). There was
an insufficient number of cases with definition 3 to
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C) and NRM (E, F, and G). The dotted lines indicate patients with pre-
plantation pulmonary restriction. Three definitions of pretransplantation
FEV1/FVC ratio. 0.7 (B and E), TLC\80%, FEV1/FVC ratio. 0.7, and
ifferences between patients with and without pulmonary restriction in
C, P 5 .012) and cumulative incidence of NRM (D, P\ .0001; E, P\
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Restrictive lungdisease alsowas significantly associ-
ated with an increased risk of NRM (HR 5 2.41; 95%
CI5 1.98-2.94;P\ .001) (Table 5). Sensitivity analyses
using the alternative definitions revealed that the associ-
ation remained significant. According to definition 2,
the presence of a restrictive pattern was associated
with a 2-fold increase in the risk of NRM (HR5 2.39;
95%CI5 1.95-2.92;P\ .001). According to definition
3, the presence of a restrictive pattern was still signifi-
cantly associated with a 2-fold increase in the risk of
NRM (HR5 1.98; 95%CI5 1.57-2.50;P\ .001).Us-
ing each of the 3 definitions of pulmonary restriction,
the cumulative incidence of NRMwas significantly dif-
ferent between patientswith andwithout pulmonary re-
striction (P\ .0001) (Figure 1D, E, and F).
We also repeated these analyses after adjusting for
disease risk and year of transplantation in the models.
The resultant point estimates were decreased slightly,
but the association between pulmonary restriction and
nonrelapse mortality remained statistically significant
for all 3 definitions of pulmonary restriction (Table 4).
We also performed stratified analyses of the adjusted
models based on conditioning regimen. Among patients
who received anMAconditioning regimen, the presence
of pretransplantation pulmonary restriction remained
significantly associated with increased risk of NRM
(definition1:HR5 2.07, 95%CI5 1.68-2.56,P\.001;
definition 2: HR 5 2.10, 95% CI 5 1.70-2.60, P\
.001; definition 3: HR 5 1.74, 95% CI 5 1.37-2.22,
P\ .001). Among patients who received an RIC regi-
men, the association with NRM was neither consistent
nor statistically significant with each definition for pre-
transplantation pulmonary restriction (definition 1:
HR 5 1.69, 95% CI 5 0.86-3.32, P 5 .125; definition
2:HR5 1.18, 95%CI5 0.55-2.56,P5 .669; definition
3: HR5 0.59, 95% CI5 0.17-2.04, P5 .404).DISCUSSION
Evaluation of pulmonary function serves as an im-
portant method for risk stratification of patients whoTable 5. Sensitivity Analysis of the Association between Pretransp
n (%) Events
U
HR (95% CI)
TLC < 80%
No 2351 (92) 261 —
Yes 194 (8) 43 2.41 (1.98-2.94
TLC < 80% + FEV1/FVC > 0.7
No 2358 (93) 263 —
Yes 185 (7) 41 2.39 (1.95-2.92
TLC < 80% + FEV1/FVC > 0.7 + low-probability chest imaging
No 2396 (93) 275 —
Yes 143 (6) 28 1.98 (1.57-2.50
*Adjusted for disease risk and year.are considering allogeneic HCT [7,8,10,23-25]. The
most recent studies clearly indicate that the presence
of poor lung function before HCT is associated with
worse outcomes, including respiratory failure and
mortality [7,24]. But, these studies, along with many
others, are limited in their ability to comment on the
potential biological mechanisms by which poor lung
function might influence a patient’s posttransplanta-
tion clinical course. The literature contains 2 possible
explanations for these repeated observations: (1) Im-
paired lung function likely leaves a patient with less
pulmonary reserve, meaning less lung capacity for sur-
viving a period of critical illness, and (2) previous lung
injury may have immunologically primed the lungs,
predisposing the lungs to additional immunologic in-
jury during the transplantation process. Based on the
observations of our current analysis, we suspect that
there may be a third explanation linked to pulmonary
restriction and respiratory muscle weakness.
Pretransplantation pulmonary restriction is a sig-
nificant clinical problem. In the current study, we
found that the prevalence of pulmonary restriction
among transplantation candidates was only 8%, which
is much lower than a previously reported prevalence of
29% in a study of patients who underwent transplanta-
tion between 1984 and 1990, an entirely different era
of stem cell transplantation [2,12,15]. Given the obser-
vations associated with our most stringent definition of
pulmonary restriction, we suspect that the majority of
these patients with pulmonary restriction (77%) likely
had evidence of respiratory muscle weakness before
transplantation. This supposition is supported by 2
observations. First, there was a direct correlation
between BMI and TLC values; patients with lower
BMI, who may be more likely to be physiologically de-
conditioned because poor nutritional status, had lower
TLC values. Second, there also was a significant rela-
tionship between disease type/risk and the degree of
TLC reduction. Although this could indicate that pa-
tients with the most advanced disease were more likely
to have had thoracic or pulmonary injury resulting in
pulmonary restriction, patients who had radiographic
evidence of parenchymal or thoracic abnormalitieslantation Restriction and Nonrelapse Mortality
nadjusted Adjusted*
P Value HR (95% CI) P Value
—
) < .001 2.18 (1.79-2.65) <.001
—
) < .001 2.18 (1.78-2.66) <.001
—
) < .001 1.82 (1.44-2.30) <.001
Biol Blood Marrow Transplant 16:199-206, 2010 205Pulmonary Restriction and Mortality after HCTthat could cause restrictive lung disease were in the mi-
nority. Instead, we believe that this group of patients
were most likely to be physiologically deconditioned
because of multiple previous rounds of aggressive can-
cer treatment. Based on these observations, our results
go beyond confirming that the presence of pulmonary
restriction before transplantation was associated with
a higher risk of respiratory failure and NRM. Our
study provides the first published evidence that pre-
transplantation pulmonary restriction may be caused
by respiratory muscle weakness. This may partially ex-
plain the well-established relationship between poor
lung function and worse allogeneic HCT outcome.
Our analysis accounted for the major variables that
could influence pulmonary function. First, as clearly
demonstrated by the significant relationship between
disease risk and pretransplantation pulmonary restric-
tion, we included disease risk as a potential confound-
ing variable. Whereas this inclusion attenuated the
magnitude of the effect associated with pretransplanta-
tion pulmonary restriction, we demonstrated that
despite this adjustment, this relationship with the
two outcomes remained statistically significant. Sec-
ond, we also accounted for potential changes in patient
selection over the course of the 14-year study period by
including the year of transplantation in our models.
Again, this did not significantly influence our results,
suggesting that this relationship is durable despite
temporal changes related to transplantation proce-
dures and patient selection. Third, recognizing the
potential physiological differences in the patient
populations receiving MA versus RIC regimens, we
stratified our analyses accordingly, and found that al-
though the association remained strong in patients
who received an MA regimen, it was less so for those
who received an RIC regimen. Nevertheless, we note
that, at least for the respiratory failure endpoint, the
point estimates for the RIC patients were similar in
magnitude to those observed among the MA patients.
Our cohort may have been underpowered to demon-
strate statistical significance for the RIC patients
with respect to mortality.
Our study is subject to the usual limitations associ-
ated with single-center retrospective studies. In addi-
tion, perhaps the study’s most noteworthy limitation
is the lack of data from direct measurements of respira-
tory muscle strength with such tools as maximum
inspiratory and expiratory pressures, or even indirectly
with grip strength.Wewere only able to infer that a re-
strictive pattern noted on PFTs, in the absence of any
radiographic features that may explain the restrictive
pattern, was most likely attributable to respiratory
muscle weakness. However, respiratory muscle dys-
function is often present before pulmonary restriction
is apparent on PFTs [26-28], suggesting that we have
most likely underestimated the prevalence of respira-
tory muscle dysfunction. Although data for respiratorymuscle strength are not available in our database, we
believe that such measurements not only could con-
tribute significantly to our understanding of this
process, but also help direct clinical care with interven-
tions that can increase respiratory muscle strength.
Future prospective studies should consider incorporat-
ing relatively simple tools for measuring respiratory
muscle function (eg, maximum inspiratory and expira-
torypressures),whichare available throughmostpulmo-
nary function testing laboratories, to evaluate patients
with and without a pretransplantation TLC\80%.
In summary, the results from the current study
demonstrate that pretransplantation restrictive lung
disease is a risk factor for allogeneic HCT outcomes
and possibly may be attributable to respiratory muscle
weakness. This may partially explain the higher risk for
poor transplantation outcome that has long been asso-
ciated with poor pretransplantation lung function. If
this is confirmed, future studies should consider evalu-
ating interventions aimed at strengthening respiratory
muscles to determine whether such measures can
improve the outcomes of allogeneic HCT.ACKNOWLEDGMENTS
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